CN1476908A - 球形氨基酸吸附剂及其制备方法 - Google Patents
球形氨基酸吸附剂及其制备方法 Download PDFInfo
- Publication number
- CN1476908A CN1476908A CNA031304036A CN03130403A CN1476908A CN 1476908 A CN1476908 A CN 1476908A CN A031304036 A CNA031304036 A CN A031304036A CN 03130403 A CN03130403 A CN 03130403A CN 1476908 A CN1476908 A CN 1476908A
- Authority
- CN
- China
- Prior art keywords
- aminoacid
- adsorbent
- carrier
- spherical
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 74
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 239000003463 adsorbent Substances 0.000 title claims description 81
- 201000010099 disease Diseases 0.000 claims abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 24
- LRWZZZWJMFNZIK-UHFFFAOYSA-N 2-chloro-3-methyloxirane Chemical compound CC1OC1Cl LRWZZZWJMFNZIK-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229920005989 resin Polymers 0.000 claims abstract description 18
- 239000011347 resin Substances 0.000 claims abstract description 18
- 206010028417 myasthenia gravis Diseases 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 16
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 16
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims abstract description 12
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 10
- 208000037487 Endotoxemia Diseases 0.000 claims abstract description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 7
- 239000002253 acid Substances 0.000 claims abstract description 6
- 230000004913 activation Effects 0.000 claims abstract description 6
- 229920001184 polypeptide Polymers 0.000 claims abstract description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 5
- 235000001014 amino acid Nutrition 0.000 claims description 70
- 229940024606 amino acid Drugs 0.000 claims description 70
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 53
- 229920002678 cellulose Polymers 0.000 claims description 28
- 239000001913 cellulose Substances 0.000 claims description 28
- 239000000243 solution Substances 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 238000006243 chemical reaction Methods 0.000 claims description 21
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 19
- 229920001817 Agar Polymers 0.000 claims description 17
- 229920000742 Cotton Polymers 0.000 claims description 17
- 229920000297 Rayon Polymers 0.000 claims description 17
- 239000008272 agar Substances 0.000 claims description 17
- 230000001951 hemoperfusion Effects 0.000 claims description 15
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 13
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 13
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 13
- 239000003960 organic solvent Substances 0.000 claims description 13
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 13
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 12
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 11
- 229920005615 natural polymer Polymers 0.000 claims description 11
- 238000002560 therapeutic procedure Methods 0.000 claims description 11
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 10
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- 238000004321 preservation Methods 0.000 claims description 9
- 235000018102 proteins Nutrition 0.000 claims description 9
- 229920000936 Agarose Polymers 0.000 claims description 8
- 206010040070 Septic Shock Diseases 0.000 claims description 8
- 239000003513 alkali Substances 0.000 claims description 8
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- 229920001661 Chitosan Polymers 0.000 claims description 7
- 108010010803 Gelatin Proteins 0.000 claims description 7
- 229920001503 Glucan Polymers 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 7
- 235000010489 acacia gum Nutrition 0.000 claims description 7
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 7
- 239000008273 gelatin Substances 0.000 claims description 7
- 229920000159 gelatin Polymers 0.000 claims description 7
- 235000019322 gelatine Nutrition 0.000 claims description 7
- 235000011852 gelatine desserts Nutrition 0.000 claims description 7
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 7
- 229940057995 liquid paraffin Drugs 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 229920003002 synthetic resin Polymers 0.000 claims description 7
- 239000000057 synthetic resin Substances 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 6
- 235000013922 glutamic acid Nutrition 0.000 claims description 6
- 239000004220 glutamic acid Substances 0.000 claims description 6
- 230000036303 septic shock Effects 0.000 claims description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 5
- 230000032683 aging Effects 0.000 claims description 5
- 230000008878 coupling Effects 0.000 claims description 5
- 238000010168 coupling process Methods 0.000 claims description 5
- 238000005859 coupling reaction Methods 0.000 claims description 5
- 229940096992 potassium oleate Drugs 0.000 claims description 5
- MLICVSDCCDDWMD-KVVVOXFISA-M potassium;(z)-octadec-9-enoate Chemical compound [K+].CCCCCCCC\C=C/CCCCCCCC([O-])=O MLICVSDCCDDWMD-KVVVOXFISA-M 0.000 claims description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 5
- 238000010792 warming Methods 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 4
- 239000002270 dispersing agent Substances 0.000 claims description 4
- 125000003700 epoxy group Chemical group 0.000 claims description 4
- 238000009413 insulation Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000012670 alkaline solution Substances 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- 108010039918 Polylysine Proteins 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 230000006229 amino acid addition Effects 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- 229920000656 polylysine Polymers 0.000 claims description 2
- 238000006116 polymerization reaction Methods 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 abstract description 29
- 230000000694 effects Effects 0.000 abstract description 9
- 241001465754 Metazoa Species 0.000 abstract description 5
- 230000008081 blood perfusion Effects 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 5
- 238000012360 testing method Methods 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003446 ligand Substances 0.000 abstract 2
- 238000004140 cleaning Methods 0.000 abstract 1
- 230000001524 infective effect Effects 0.000 abstract 1
- 229920002521 macromolecule Polymers 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 description 24
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 238000011282 treatment Methods 0.000 description 15
- 206010028372 Muscular weakness Diseases 0.000 description 13
- 239000002250 absorbent Substances 0.000 description 13
- 230000036473 myasthenia Effects 0.000 description 13
- 241000219146 Gossypium Species 0.000 description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 10
- 102000003390 tumor necrosis factor Human genes 0.000 description 10
- 102100040247 Tumor necrosis factor Human genes 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108010009685 Cholinergic Receptors Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 102000034337 acetylcholine receptors Human genes 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- YXXURDJTDAAEPH-UHFFFAOYSA-N 2-aminopropanethioic s-acid Chemical compound CC(N)C(S)=O YXXURDJTDAAEPH-UHFFFAOYSA-N 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000034486 Multi-organ failure Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000009514 concussion Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 231100000284 endotoxic Toxicity 0.000 description 2
- 230000002346 endotoxic effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002118 epoxides Chemical class 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229960001866 silicon dioxide Drugs 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 238000010557 suspension polymerization reaction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- BFVQTKQTUCQRPI-YYEZTRBPSA-N LPS with O-antigen Chemical compound O([C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]5[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O5)O)O4)O)[C@@H](O)[C@@H](CO)O3)NC(C)=O)[C@@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)NC(C)=O)O2)NC(C)=O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)OC([C@@H]1O)O[C@H]1[C@H](O)[C@@H]([C@@H](O)COC2[C@H]([C@@H](O)[C@H](OP(O)(O)=O)[C@@H]([C@@H](O)CO)O2)O)OC([C@H]1O)O[C@H]1[C@H](OP(O)(=O)OP(O)(=O)OCCN)[C@@H]([C@@H](O)CO)OC([C@H]1O)O[C@H]1[C@H](O[C@]2(O[C@@H]([C@@H](O)[C@H](O[C@]3(O[C@@H]([C@@H](O)[C@H](OP(O)(=O)OCCN)C3)[C@@H](O)CO)C(O)=O)C2)[C@@H](O)CO)C(O)=O)C[C@](O[C@@H]1[C@@H](O)CO)(OC[C@H]1O[C@@H](OC[C@@H]2[C@H]([C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O2)O)[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H]([C@@H]1OP(O)(O)=O)OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O BFVQTKQTUCQRPI-YYEZTRBPSA-N 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000002164 acetylcholinergic effect Effects 0.000 description 1
- 238000002479 acid--base titration Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- -1 amine amino acid Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940124645 emergency medicine Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000013546 non-drug therapy Methods 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
Landscapes
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- External Artificial Organs (AREA)
Abstract
Description
项目 | 生化指标 | 血液灌流组(8只) | 对照组(5只) | |
灌流前 | 灌流后 | |||
内毒素 | LPS水平(EU/ml) | 5.56 | 0.41 | 5.26 |
肝功能 | 白蛋白(g/l) | 26.73 | 23.16 | 24.28 |
总胆红素(mg/dl) | 0.047 | 0.051 | 0.091 | |
谷丙转氨酶(U/L) | 34.3 | 24.8 | 41.4 | |
谷草转氨酶(U/L) | 15.3 | 14.1 | 35.7 | |
碱性磷酸酶(U/L) | 109.4 | 118.1 | 195.5 | |
肾功能 | 尿素氮(mmol/L) | 5.17 | 4.62 | 7.83 |
肌酐(umol/L) | 62.74 | 70.86 | 94.33 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03130403 CN1269535C (zh) | 2003-07-15 | 2003-07-15 | 球形氨基酸吸附剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03130403 CN1269535C (zh) | 2003-07-15 | 2003-07-15 | 球形氨基酸吸附剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1476908A true CN1476908A (zh) | 2004-02-25 |
CN1269535C CN1269535C (zh) | 2006-08-16 |
Family
ID=34153729
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03130403 Expired - Lifetime CN1269535C (zh) | 2003-07-15 | 2003-07-15 | 球形氨基酸吸附剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1269535C (zh) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1325155C (zh) * | 2004-08-27 | 2007-07-11 | 中国科学院海洋研究所 | 一种大分子色素蛋白的吸附基质及应用 |
CN100371034C (zh) * | 2004-03-12 | 2008-02-27 | 中国科学院大连化学物理研究所 | 组氨酸在血液净化亲合吸附介质中的应用 |
CN101185880B (zh) * | 2007-08-22 | 2010-05-19 | 大连理工大学 | 一种用于抗体清除的血液净化吸附剂及其制备方法 |
CN102350309A (zh) * | 2011-06-30 | 2012-02-15 | 浙江工业大学 | 一种基于磁性壳聚糖微球的内毒素吸附介质及其使用方法 |
CN102423721A (zh) * | 2011-08-18 | 2012-04-25 | 浙江工业大学 | 一种磁性阴离子交换剂及其作为内毒素吸附介质的应用 |
CN102527341A (zh) * | 2012-02-03 | 2012-07-04 | 珠海健帆生物科技股份有限公司 | 一种用于血液净化的免疫吸附剂及其制备方法 |
CN103230781A (zh) * | 2013-05-03 | 2013-08-07 | 重庆大学 | 一种用于血液净化法去除内毒素的肝素-苯丙氨酸吸附材料 |
CN103285826A (zh) * | 2013-06-28 | 2013-09-11 | 天津优纳斯生物科技有限公司 | 一种用于抑制肿瘤生长与转移的血液净化吸附剂及其应用 |
CN103447009A (zh) * | 2013-09-26 | 2013-12-18 | 济南大学 | 一种半胱氨酸改性丝瓜络吸附剂的制备及应用 |
CN103467622A (zh) * | 2013-09-24 | 2013-12-25 | 盐城工学院 | 苯丙氨酸修饰的壳聚糖衍生物及其制备方法与应用 |
CN104045734A (zh) * | 2014-07-08 | 2014-09-17 | 中国海洋大学 | 一种对展青霉素具有高效吸附作用的树脂制备方法 |
CN104959120A (zh) * | 2015-06-19 | 2015-10-07 | 佛山市博新生物科技有限公司 | 一种用于血液灌流的炎性因子吸附剂及制备方法 |
CN105664868A (zh) * | 2016-01-22 | 2016-06-15 | 广州康盛生物科技有限公司 | 血液净化用内毒素吸附材料及其制备方法与应用 |
CN105688841A (zh) * | 2014-11-25 | 2016-06-22 | 中国科学院大连化学物理研究所 | 一种免疫吸附高分子微球及其制备和应用 |
CN106000350A (zh) * | 2016-05-12 | 2016-10-12 | 大连理工大学 | 抗人β2微球蛋白的血液净化吸附剂及其制备方法和用途 |
CN108855003A (zh) * | 2018-06-28 | 2018-11-23 | 南开大学 | 一种用于清除血液中炎性因子的免疫吸附剂及其制备方法 |
CN109772269A (zh) * | 2017-11-13 | 2019-05-21 | 天津红日药业股份有限公司 | 一种内毒素吸附剂及其制备方法和用途 |
CN109997940A (zh) * | 2019-03-24 | 2019-07-12 | 聂长青 | 一种玫瑰咖啡及其制备方法 |
CN111632202A (zh) * | 2020-06-29 | 2020-09-08 | 南开大学 | 肿瘤细胞粘附材料及其制备方法和应用 |
CN112871139A (zh) * | 2020-12-24 | 2021-06-01 | 武汉大学 | 一种全血灌流吸附剂、其制备方法及应用 |
CN114950375A (zh) * | 2022-06-02 | 2022-08-30 | 杭州隆基生物技术有限公司 | 链霉亲和素琼脂糖磁珠及其制备方法和运用 |
CN115739031A (zh) * | 2021-09-02 | 2023-03-07 | 中国科学院理化技术研究所 | 壳聚糖或其衍生物在脱除明胶中内毒素的应用 |
CN117986664A (zh) * | 2024-01-11 | 2024-05-07 | 重庆希尔康血液净化器材研发有限公司 | 一种用于清除内毒素的吸附材料及制备方法和应用 |
-
2003
- 2003-07-15 CN CN 03130403 patent/CN1269535C/zh not_active Expired - Lifetime
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100371034C (zh) * | 2004-03-12 | 2008-02-27 | 中国科学院大连化学物理研究所 | 组氨酸在血液净化亲合吸附介质中的应用 |
CN1325155C (zh) * | 2004-08-27 | 2007-07-11 | 中国科学院海洋研究所 | 一种大分子色素蛋白的吸附基质及应用 |
CN101185880B (zh) * | 2007-08-22 | 2010-05-19 | 大连理工大学 | 一种用于抗体清除的血液净化吸附剂及其制备方法 |
CN102350309A (zh) * | 2011-06-30 | 2012-02-15 | 浙江工业大学 | 一种基于磁性壳聚糖微球的内毒素吸附介质及其使用方法 |
CN102423721A (zh) * | 2011-08-18 | 2012-04-25 | 浙江工业大学 | 一种磁性阴离子交换剂及其作为内毒素吸附介质的应用 |
CN102423721B (zh) * | 2011-08-18 | 2013-07-24 | 浙江工业大学 | 一种磁性阴离子交换剂及其作为内毒素吸附介质的应用 |
CN102527341B (zh) * | 2012-02-03 | 2015-06-10 | 珠海健帆生物科技股份有限公司 | 一种用于血液净化的免疫吸附剂及其制备方法 |
CN102527341A (zh) * | 2012-02-03 | 2012-07-04 | 珠海健帆生物科技股份有限公司 | 一种用于血液净化的免疫吸附剂及其制备方法 |
CN103230781A (zh) * | 2013-05-03 | 2013-08-07 | 重庆大学 | 一种用于血液净化法去除内毒素的肝素-苯丙氨酸吸附材料 |
CN103285826A (zh) * | 2013-06-28 | 2013-09-11 | 天津优纳斯生物科技有限公司 | 一种用于抑制肿瘤生长与转移的血液净化吸附剂及其应用 |
CN103467622B (zh) * | 2013-09-24 | 2016-05-25 | 盐城工学院 | 苯丙氨酸修饰的壳聚糖衍生物及其制备方法与应用 |
CN103467622A (zh) * | 2013-09-24 | 2013-12-25 | 盐城工学院 | 苯丙氨酸修饰的壳聚糖衍生物及其制备方法与应用 |
CN103447009A (zh) * | 2013-09-26 | 2013-12-18 | 济南大学 | 一种半胱氨酸改性丝瓜络吸附剂的制备及应用 |
CN104045734A (zh) * | 2014-07-08 | 2014-09-17 | 中国海洋大学 | 一种对展青霉素具有高效吸附作用的树脂制备方法 |
CN105688841A (zh) * | 2014-11-25 | 2016-06-22 | 中国科学院大连化学物理研究所 | 一种免疫吸附高分子微球及其制备和应用 |
CN105688841B (zh) * | 2014-11-25 | 2018-02-23 | 中国科学院大连化学物理研究所 | 一种免疫吸附高分子微球及其制备和应用 |
CN104959120A (zh) * | 2015-06-19 | 2015-10-07 | 佛山市博新生物科技有限公司 | 一种用于血液灌流的炎性因子吸附剂及制备方法 |
CN105664868A (zh) * | 2016-01-22 | 2016-06-15 | 广州康盛生物科技有限公司 | 血液净化用内毒素吸附材料及其制备方法与应用 |
CN106000350A (zh) * | 2016-05-12 | 2016-10-12 | 大连理工大学 | 抗人β2微球蛋白的血液净化吸附剂及其制备方法和用途 |
CN109772269A (zh) * | 2017-11-13 | 2019-05-21 | 天津红日药业股份有限公司 | 一种内毒素吸附剂及其制备方法和用途 |
CN109772269B (zh) * | 2017-11-13 | 2022-06-21 | 天津红日药业股份有限公司 | 一种内毒素吸附剂及其制备方法和用途 |
CN108855003B (zh) * | 2018-06-28 | 2021-01-05 | 南开大学 | 一种用于清除血液中炎性因子的免疫吸附剂及其制备方法 |
CN108855003A (zh) * | 2018-06-28 | 2018-11-23 | 南开大学 | 一种用于清除血液中炎性因子的免疫吸附剂及其制备方法 |
CN109997940A (zh) * | 2019-03-24 | 2019-07-12 | 聂长青 | 一种玫瑰咖啡及其制备方法 |
CN111632202A (zh) * | 2020-06-29 | 2020-09-08 | 南开大学 | 肿瘤细胞粘附材料及其制备方法和应用 |
CN112871139A (zh) * | 2020-12-24 | 2021-06-01 | 武汉大学 | 一种全血灌流吸附剂、其制备方法及应用 |
CN115739031A (zh) * | 2021-09-02 | 2023-03-07 | 中国科学院理化技术研究所 | 壳聚糖或其衍生物在脱除明胶中内毒素的应用 |
CN115739031B (zh) * | 2021-09-02 | 2024-05-28 | 中国科学院理化技术研究所 | 壳聚糖或其衍生物在脱除明胶中内毒素的应用 |
CN114950375A (zh) * | 2022-06-02 | 2022-08-30 | 杭州隆基生物技术有限公司 | 链霉亲和素琼脂糖磁珠及其制备方法和运用 |
CN114950375B (zh) * | 2022-06-02 | 2024-04-30 | 杭州隆基生物技术有限公司 | 链霉亲和素琼脂糖磁珠及其制备方法和运用 |
CN117986664A (zh) * | 2024-01-11 | 2024-05-07 | 重庆希尔康血液净化器材研发有限公司 | 一种用于清除内毒素的吸附材料及制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1269535C (zh) | 2006-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1269535C (zh) | 球形氨基酸吸附剂及其制备方法 | |
CN104959120B (zh) | 一种用于血液灌流的炎性因子吸附剂及制备方法 | |
CN1239210C (zh) | 血液灌流用内毒素吸附剂及制备方法 | |
JPH037681B2 (zh) | ||
CN103055822B (zh) | 一种用于清除血液胆红素的血液净化吸附剂及其制备方法 | |
CN107199024B (zh) | 一种用于清除血液低密度脂蛋白的吸附剂及其制备方法 | |
CN103028376B (zh) | 一种用于清除血液毒素的血液净化吸附剂及其制备方法 | |
CN102614843B (zh) | 蛋白a免疫吸附材料及其制备方法 | |
CN108855003B (zh) | 一种用于清除血液中炎性因子的免疫吸附剂及其制备方法 | |
EP3298129B1 (en) | Method of preparing universal blood product | |
CN103406111A (zh) | 用于血液灌流去除内毒素的吸附剂及其制备方法 | |
CN1250329C (zh) | 内毒素吸附剂及其制备方法 | |
CN104448101B (zh) | 一种β-受体激动剂复合模板分子印迹聚合物的制备方法及应用 | |
CN103769060B (zh) | 用于清除细菌内毒素、dna和肽聚糖的吸附剂和制备方法及用途 | |
CN103933947B (zh) | 用于清除类风湿因子的血液净化材料及其制备方法 | |
RU2641924C1 (ru) | Сорбционный материал, способ его получения и способ его применения | |
CN101747506A (zh) | 一种富集痕量恩诺沙星的分子印迹聚合物的制备方法 | |
CN108043375A (zh) | 一种多模式组合万古霉素色谱固定相的制备方法 | |
CN1111430C (zh) | 球形纤维素dna免疫吸附剂 | |
CN1229389C (zh) | 纯化基因工程重组干扰素的免疫磁性分离技术 | |
GB2343511A (en) | A method for preparing a carbonized resin DNA immunoadsorbent | |
CN102580683A (zh) | 内毒素协同吸附剂及其制备方法 | |
CN101745116B (zh) | 用于治疗威尔森氏症的铜离子螯合吸附介质的制备方法 | |
CN1718254A (zh) | 一种用于血液净化治疗的免疫吸附柱 | |
RU2366958C2 (ru) | Способ очистки крови от антител к тиреоидным гормонам с помощью иммобилизированного гранулированного магнитоуправляемого препарата |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ZHUHAI JAFRON BIOMEDICAL CO., LTD. Free format text: FORMER OWNER: NANKAI UNIVERSITY Effective date: 20110610 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 300071 NO. 94, WEIJIN ROAD, TIANJIN CITY TO: 519080 4-5/F, BUILDING 5, BUILDING 4, AREA 3, NO. 99, ZHUHAI DAXUE ROAD, ZHUHAI CITY, GUANGDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110610 Address after: 519080, 4, 3, 99, 4, 5, 5, University Road, Zhuhai, Guangdong, Zhuhai Patentee after: JAFRON BIOMEDICAL Co.,Ltd. Address before: 300071 Tianjin city Wei Jin Road No. 94 Patentee before: Nankai University |
|
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 519080 Zhuhai science and technology zone, Guangdong high tech Road No. six, No. 98 Patentee after: JAFRON BIOMEDICAL Co.,Ltd. Address before: 519080, 4, 3, 99, 4, 5, 5, University Road, Zhuhai, Guangdong, Zhuhai Patentee before: JAFRON BIOMEDICAL Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 519080 Zhuhai hi tech Zone No. six road, Guangdong Province, 98 Patentee after: JAFRON BIOMEDICAL Co.,Ltd. Address before: 519080 Zhuhai hi tech Zone No. six road, Guangdong Province, 98 Patentee before: JAFRON BIOMEDICAL Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CX01 | Expiry of patent term |
Granted publication date: 20060816 |
|
CX01 | Expiry of patent term |